Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Osteoarthritis

Clinical and regulatory intelligence for Osteoarthritis with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
11
Catalysts
0
Assets
8

Relevant assets

CBD →
Clinical →
glucosamine →
LITUS →
Musculoskeletal →
Osteoarthritis Knee →
Pilot →
Shock →

Relevant companies

Eli Lilly →

Recent signals(11)

ClinicalAugust 5, 2026

CBD Study Investigates Pain Relief for Knee Osteoarthritis

A clinical trial is underway to evaluate the efficacy of topically applied CBD for knee osteoarthritis pain relief.

ClinicalJuly 23, 2026

Shock Wave Therapy Trial for Knee Osteoarthritis Shows Potential for Clinical Practice Change

A randomized controlled trial is assessing the efficacy of shockwave therapy combined with exercise for knee osteoarthritis.

ClinicalJuly 19, 2026

Eli Lilly's Eloralintide Shows Promise for Osteoarthritis Knee Pain in Obese Patients

Eli Lilly is conducting two independent studies to evaluate the efficacy and safety of Eloralintide (LY3841136) in adults with knee osteoarthritis and obesity.

ClinicalJuly 18, 2026

Pilot Trial on Culturally Tailored Exercise Program for Hispanics with Knee OA

A pilot randomized controlled trial is being conducted to evaluate a culturally acceptable treatment program for Hispanics with knee osteoarthritis.

ClinicalJuly 7, 2026

Pilot rTMS Trial for Knee Arthritis Pain and Depression Shows Promise

A pilot trial is investigating the feasibility of rTMS combined with Tai Chi for knee OA pain and depression.

ClinicalJuly 5, 2026

Clinical Trial Evaluates Intra-Articular Ozone for Knee Osteoarthritis

A clinical trial is assessing the efficacy of varying doses of intra-articular ozone injections in knee osteoarthritis patients aged 40-75.

CompetitiveJuly 1, 2026

ZetrOZ initiates trial for LITUS in knee osteoarthritis pain relief

ZetrOZ, Inc. is conducting a trial to evaluate the efficacy of long-duration low intensity therapeutic ultrasound for knee osteoarthritis pain relief.

ClinicalJune 27, 2026

Study on Gait Biofeedback for FastOA Shows Potential for Early Intervention

A clinical trial is assessing the impact of real-time gait biofeedback on early markers of FastOA in ACL reconstructed patients.

ClinicalJune 25, 2026

Hydroxytyrosol-loaded hydrogel shows promise for cartilage regeneration in osteoarthritis

A genipin-crosslinked gelatin/PVA hydrogel effectively delivers Hydroxytyrosol, enhancing chondrocyte viability and metabolic activity.

ClinicalJune 24, 2026

Study on Ozone Injection Therapy for Knee Osteoarthritis Outcomes

A clinical trial is comparing the effects of two ozone concentrations (15 μg/mL and 25 μg/mL) in treating knee osteoarthritis.

ClinicalJune 2, 2026

Pilot Study on Geniculate Artery Embolization for Knee Osteoarthritis Initiated

A randomized pilot study is underway to evaluate the safety and efficacy of geniculate artery embolization in knee osteoarthritis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Musculoskeletal →
Orthopedics →
Osteoarthritis →
Rheumatology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.